TICKERNERD
Menu
CRISCRISHealthcare · Biotechnology

CRIS Stock Forecast: Curis, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.58

The 4 Wall Street analysts covering Curis, Inc. hold a median 12-month price target of $43 — +2621.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.8M
Ticker Nerd rank
37 / 100
Median analyst target
$43
Analysts covering
4
Ticker Nerd rank

CRIS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Curis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Growth
66
Issuance
60
Accruals
56
Revisions
48
Quality
40
Momentum
18
Volatility
13
Value
4

Size (98): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRIS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRIS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $20Median $43High $65

The green dot is the last close — the median target sits +2621.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$43
24 July 2026HC Wainwright & Co.MaintainsBuy$17 → $43
24 July 2026HC Wainwright & Co.MaintainsBuy—
20 Mar 2026HC Wainwright & Co.ReiteratesBuy—
20 Mar 2026HC Wainwright & Co.ReiteratesBuy$17
19 May 2025HC Wainwright & Co.AssumesBuy$17
31 Mar 2025HC Wainwright & Co.MaintainsBuy—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
1 Nov 2024HC Wainwright & Co.MaintainsBuy—
27 Sept 2024HC Wainwright & Co.ReiteratesBuy$26
1 Aug 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024Cantor FitzgeraldReiteratesOverweight—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024Truist SecuritiesMaintainsBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
9 Feb 2024HC Wainwright & Co.MaintainsBuy—
17 Nov 2023Truist SecuritiesInitiatesBuy—
29 Sept 2023HC Wainwright & Co.ReiteratesBuy$6.00 → $51
25 Sept 2023HC Wainwright & Co.ReiteratesBuy$6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRIS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRIS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Curis, Inc. (CRIS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.4×

Cheaper than 72% of US stocks

Price / sales
0.9×

Cheaper than 81% of US stocks

Price / book
0.2×

Cheaper than 89% of US stocks

EV / EBITDA
0.0×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−833.4%

Higher than 8% of US stocks

Net margin
0.0%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−138.8%

Higher than 2% of US stocks

Return on assets
−93.2%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRIS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRISCuris, Inc.$3.8M
37
GNPXGenprex, Inc.$3.2M
9
ARTLArtelo Biosciences, Inc.$3.2M
17
CLDICalidi Biotherapeutics, Inc.$3.5M
23
GRIGRI Bio, Inc.$3.6M
30
MTNBMatinas BioPharma Holdings, Inc.$2.9M
46
PPCBPropanc Biopharma, Inc.$3.8M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Curis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRIS news & analysis

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

PRNewsWire · 13 Aug 2026negative

Curis, Inc. announced the pricing of its $5.6 million public offering, in which new and existing healthcare-focused institutional investors will purchase roughly 3.73 million shares (or pre-funded warrants) with accompanying warrants at a combined offering price of $1.50 per share and warrant. The proceeds relate to funding the company's development of its IRAK4 and FLT3 inhibitor emavusertib.

Why it matters — CRIS watchers would care because this capital raise provides funding for the company's pipeline but issues additional shares, diluting existing shareholders.

Curis Doses First Five Patients in TakeAim CLL Study

PRNewsWire · 30 July 2026positive

Curis announced it has dosed the first five patients in its TakeAim CLL study, which evaluates emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, in patients with Chronic Lymphocytic Leukemia.

Why it matters — This enrollment milestone moves the TakeAim CLL study forward and marks progress in Curis's clinical development of emavusertib for CLL patients.

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Benzinga · 24 July 2026positive

Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib and provided expanded trial timeline guidance.

Why it matters — A CRIS watcher would care because the positive clinical data for emavusertib, a blood cancer drug, supports the company's development pipeline and a December readout is now in focus.

FAQ

Frequently asked questions about CRIS stock

What is the CRIS stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Curis, Inc. have a median 12-month price target of $43, with estimates ranging from $20 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRIS stock a buy right now?

Of the 4 analysts covering Curis, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Curis, Inc. 37 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRIS?

As at 22 Aug 2026, Curis, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will CRIS stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +2621.5% from the last close, and Ticker Nerd's factor model ranks Curis, Inc. 37 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRIS stock forecast for 2030?

No analyst covering Curis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRIS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $65 over the next 12 months.

What does Curis, Inc. do?

Curis Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of human cancers.

What is the latest news on CRIS?

The most recent item we track (PRNewsWire, 13 Aug 2026): "Curis, Inc. Announces Pricing of $5.6 Million Public Offering". Curis, Inc. announced the pricing of its $5.6 million public offering, in which new and existing healthcare-focused institutional investors will purchase roughly 3.73 million shares (or pre-funded warrants) with accompanying warrants at a combined offering price of $1.50 per share and warrant. The proceeds relate to funding the company's development of its IRAK4 and FLT3 inhibitor emavusertib.

Company

About Curis, Inc.

Curis Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of human cancers. The company concentrates on first-in-class and differentiated drugs, primarily small-molecule inhibitors that target key signaling pathways involved in hematologic malignancies and solid tumors. Its lead candidate, emavusertib (CA-4948), is an orally available inhibitor of IRAK4 and FLT3 being evaluated in Phase 1/2 studies for conditions such as non-Hodgkin lymphomas, primary central nervous system lymphoma, acute myeloid leukemia, myelodysplastic syndromes, and chronic lymphocytic leukemia, often in combination with BTK inhibitors. Curis also has additional clinical programs, including CI-8993, a monoclonal antibody targeting immune regulation, and other oncology assets within its pipeline. The company collaborates with partners such as Aurigene Discovery Technologies and the National Cancer Institute to advance its research and clinical development. Headquartered in Lexington, Massachusetts, Curis Inc. plays a specialized role in the oncology market by advancing targeted cancer therapies designed to improve patient outcomes.

CEO Mr. James E. Dentzer · 20 employees · United States · https://www.curis.com